On March 17, 2026, bioAffinity Technologies, Inc. announced a clinical case study demonstrating the value of CyPath® Lung, a noninvasive lung cancer test, for high-risk patients with multiple pulmonary nodules.
AI Assistant
BIOAFFINITY TECHNOLOGIES INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.